

25 February 2026

Treatment of Mantle Cell Lymphoma (MCL)

1. How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to?

The information below has been collated from the EPIC system (not officially verified).

1st February 2025 to 31st January 2026

Belfast Trust - Belfast City Hospital Haematology Treatment

15 patients noted to have attended Haematology, Bridgewater Suite (BWS) for treatment with a diagnosis of MCL.

Belfast Trust – Belfast City Hospital Haematology Clinics

28 patients noted to have attended for review at Haematology BWS Clinics with a diagnosis of MCL.

2. How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

- BR (Bendamustine + rituximab)
- VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)
- R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)
- R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)
- CVP (cyclophosphamide, vincristine and prednisolone)
- Brukinsa (zanubrutinib)
- Imbruvica (ibrutinib)
- Velcade (bortezomib) + chemotherapy
- Tecartus (brexucabtegene autoleucl)
- R-BAC (rituximab, bendamustine and cytarabine)
- R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)
- Any other systemic anti-cancer therapy
- Wait and watch (monitoring only, no active treatment)

Belfast Trust does not hold this information centrally, as electronic prescribing is not in place for Haematology. To retrieve it would require a manual trawl of individual patient records, which would take more than 18 hours.

25 February 2026

Belfast Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

3. How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

For this question, please only count patients that have received the below treatments for the first time.

- **BR (Bendamustine + rituximab)**
- **VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)**
- **R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)**
- **R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)**
- **CVP (cyclophosphamide, vincristine and prednisolone)**
- **Brukinsa (zanubrutinib)**
- **Imbruvica (ibrutinib)**
- **Velcade (bortezomib) + chemotherapy**
- **Tecartus (CAR-T)**
- **R-BAC (rituximab, bendamustine and cytarabine)**
- **R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)**
- **Any other systemic anti-cancer therapy**
- **Wait and watch (monitoring only, no active treatment)**

Belfast Trust does not hold this information centrally, as electronic prescribing is not in place for Haematology. To retrieve it would require a manual trawl of individual patient records, which would take more than 18 hours.

4. If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials?

Mantle cell lymphoma is treated in Belfast Trust but, unfortunately, we do not currently have any open clinical trials.